Maze Therapeutics released topline phase 2 results for its genetic kidney disease program MZE829, reporting an average 35.6% reduction in disease-related measures. The company’s readout put the candidate in the same target arena as Vertex’s kidney program, intensifying the competitive focus on efficacy and durability in genetic nephropathies. Despite early optimism from analysts about “best-in-class potential,” the stock sold off as investors weighed the strength and completeness of the dataset. The divergence underscores how rare-disease oncology progress can still be judged harshly when trial power, comparator context, or endpoint durability are unclear. Investors will look for further updates to confirm whether MZE829 can convert phase 2 promise into registrational-grade evidence and maintain momentum through the next development phase.